文献速递乳腺癌

HER2低表达与HER2零表达在淋巴结阴性乳腺癌中的长期预后意义

Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer.
PubMed 文献 · Eur J Cancer · 2022-07-12

该回顾性队列研究纳入1985至2000年间未接受辅助全身治疗的410例连续淋巴结阴性乳腺癌患者,中位随访16.73年。351例HER2阴性患者中,HER2低表达198例(56.4%),HER2零表达153例(43.6%)。HER2低表达患者的无病生存期和总生存期均显著优于HER2零表达患者,多因素分析证实HER2状态为独立预后因素。

要点

  • HER2低表达患者15年无病生存率为67.5%,HER2零表达为47.3%,差异显著(P<0.001)。
  • HER2低表达患者15年总生存率为75.4%,HER2零表达为66.8%,差异显著(P=0.009)。
  • 总生存期差异见于激素受体阳性肿瘤(P=0.039),激素受体阴性肿瘤中未观察到显著差异(P=0.086)。

核心结论

  • HER2低表达患者的生存优于HER2零表达患者。

研究设计与样本

  • 回顾性队列研究,纳入1985至2000年间未接受辅助全身治疗的410例连续淋巴结阴性乳腺癌患者,中位随访16.73年(IQR 8.58-23.45年)。
  • 351例(85.6%)为HER2阴性,其中HER2零表达(免疫组化评分0)153例(43.6%),HER2低表达(免疫组化评分1+或2+且原位杂交阴性)198例(56.4%)。
  • 170例(48.4%)患者有HER2基因表达数据。

主要发现

  • HER2零表达与HER2低表达肿瘤在组织学分级(P=0.001)、Ki-67(P=0.013)和HER2基因表达(P=0.002)方面存在显著差异。
  • HER2低表达患者15年无病生存率为67.5%(95%CI 61.0-74.7),HER2零表达患者为47.3%(95%CI 39.9-56.1),差异显著(P<0.001)。
  • HER2低表达患者15年总生存率为75.4%(95%CI 69.4-81.9),HER2零表达患者为66.8%(95%CI 59.5-74.9),差异显著(P=0.009)。
  • 总生存期差异见于激素受体阳性肿瘤(P=0.039),激素受体阴性肿瘤中未观察到显著差异(P=0.086)。
  • 多因素分析证实HER2状态为独立预后因素:无病生存期HR 0.546(95%CI 0.402-0.743,P<0.001);总生存期HR 0.653(95%CI 0.458-0.932,P=0.019)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recently, novel antibody--drug conjugates (ADCs) showed clinical activity in a subset of advanced human epidermal growth factor receptor 2 (HER2)-negative patients. We investigated the prognostic significance of HER2-low and HER2-zero tumours. PATIENTS AND METHODS: The retrospective cohort study included 410 consecutive node-negative breast cancer patients without adjuvant systemic therapy treated between 1985 and 2000 (median follow-up: 16.73 [IQR 8.58-23.45] years). 351 (85.6%) were HER-2 negative and subdivided into HER2-zero (immunohistochemistry [IHC] score 0) and HER2-low (IHC score 1+ or 2+/in situ hybridisation [ISH]-negative). HER2 gene expression was available in 170 (48.4%) patients. Differences in HER2 status for immunohistochemistry, gene expression and clinico-pathologic parameters were assessed using Fisher's exact test, Pearson's correlation and Mann-Whitney test. Prognosis was investigated using the Kaplan-Meier method and Cox regression analyses. RESULTS: Of the 351 HER2-negative patients, 198 (56.4%) had HER2-low tumours and 153 (43.6%) were HER2-zero. Significant differences between HER2-zero and HER2-low tumours were found in histologic grading (P = 0.001), Ki-67 (P = 0.013) and HER2 gene expression (P = 0.002). HER2-low patients had significantly longer disease-free survival (DFS) (15-year rate: 67.5% [95% CI 61.0-74.7] vs. 47.3% [95% CI 39.9-56.1], P < 0.001) and overall survival (OS) (15-year rate: 75.4% [95% CI 69.4-81.9] vs. 66.8% [95% CI 59.5-74.9], P = 0.009). The OS difference was observed in hormone receptor (HR)-positive (P = 0.039) but not HR-negative (P = 0.086) tumours. The results of multivariable analyses confirmed the independent prognostic significance of HER2 status (DFS: HR, 0.546; 95% CI, 0.402-0.743; P < 0.001; OS: HR, 0.653; 95% CI, 0.458-0.932; P = 0.019). CONCLUSION: HER2-low patients had a better survival than HER2-zero patients.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Almstedt K, Heimes AS, Kappenberg F, et al. Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer. Eur J Cancer. 2022. PMID: 35839597. doi:10.1016/j.ejca.2022.06.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。